Key result
LAAC case reports anticoagulation-related spinal epidural hematoma and subsequent large device-related thrombosis.
Why the study?
Anticoagulation-related spinal epidural hematoma and device-related thrombosis are rare but serious complications following left atrial appendage closure.
Case Report (n=1)
This case highlights the need for dynamic, individualized antithrombotic strategies in high-risk patients undergoing LAAC to manage rare but serious complications like spinal epidural hematoma and device-related thrombosis.
Vigilance for spinal epidural hematoma and device-related thrombosis is warranted after LAAC in elderly patients; leaves open optimal antithrombotic therapy.
BACKGROUND: Left atrial appendage closure (LAAC) is an important approach for stroke prevention in patients with non-valvular atrial fibrillation. Anticoagulation-related spinal epidural hematoma (SEH) and device-related thrombosis (DRT) are rare but serious complications. CASE SUMMARY: We report the case of an 86-year-old female who presented with a six-month history of recurrent chest tightness. She was clinically diagnosed with persistent non-valvular atrial fibrillation and chronic heart failure. Following a comprehensive evaluation, she underwent successful LAAC and was started on edoxaban 30 mg once daily for anticoagulation. At six weeks post-procedure, she developed an anticoagulation-related SEH. Anticoagulation was immediately discontinued. Following conservative management, the hematoma resolved and her muscle strength improved. She was subsequently started on clopidogrel 75 mg once daily for antiplatelet therapy. At the six-month follow-up, transthoracic echocardiography and computed tomography angiography confirmed a large DRT in the left atrium. Anticoagulation was re-initiated with low-molecular-weight heparin bridging to warfarin, with the international normalized ratio maintained between 2.0 and 2.5. Follow-up imaging at eight months demonstrated significant resolution of the left atrial thrombus. During the remainder of the follow-up period, no further major adverse events, including ischemic stroke or bleeding, occurred. CONCLUSION: For patients with multiple high-risk factors undergoing LAAC, attention should be paid to dynamic adjustment of individualized antithrombotic strategies, enhancement of perioperative procedural quality control, and structured follow-up within key time windows, in order to minimize the risk of complications and optimize the net clinical benefit.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a case report in persistent non-valvular atrial fibrillation and chronic heart failure (n=1). Left atrial appendage closure (LAAC) was evaluated. Left atrial appendage closure in an 86-year-old female was complicated by an anticoagulation-related spinal epidural hematoma at 6 weeks and a large device-related thrombosis at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: